ES2571111T3 - Método de diagnóstico para predicción de la respuesta de un paciente a la quimioviroterapia o radioviroterapia - Google Patents

Método de diagnóstico para predicción de la respuesta de un paciente a la quimioviroterapia o radioviroterapia

Info

Publication number
ES2571111T3
ES2571111T3 ES11746432T ES11746432T ES2571111T3 ES 2571111 T3 ES2571111 T3 ES 2571111T3 ES 11746432 T ES11746432 T ES 11746432T ES 11746432 T ES11746432 T ES 11746432T ES 2571111 T3 ES2571111 T3 ES 2571111T3
Authority
ES
Spain
Prior art keywords
patient
chemovirotherapy
radiovirotherapy
predicting
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11746432T
Other languages
English (en)
Inventor
Nathalia Giese
Jens Werner
Markus Büchler
Thomas Giese
Laurent Däffler
Celina Cziepluch
Jean Rommelaere
Zahari Raykov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Universitaet Heidelberg
Universitaetsklinikum Heidelberg
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Universitaet Heidelberg
Universitaetsklinikum Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ, Universitaet Heidelberg, Universitaetsklinikum Heidelberg filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2571111T3 publication Critical patent/ES2571111T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método de diagnóstico para predecir la respuesta de un paciente a la quimioviroterapia o radioviroterapia, que comprende (a) exponer células de tumor primario de una muestra de tumor obtenida de un paciente a dosis diferentes de (i) un parvovirus y (ii) un agente quimioterapéutico o radioterapia; y (b) determinar la reducción de la expresión o concentración de ISG15 durante periodos de tiempo variables.
ES11746432T 2010-04-30 2011-04-29 Método de diagnóstico para predicción de la respuesta de un paciente a la quimioviroterapia o radioviroterapia Active ES2571111T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004592A EP2383577A1 (en) 2010-04-30 2010-04-30 Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
PCT/EP2011/002154 WO2011134670A2 (en) 2010-04-30 2011-04-29 Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy

Publications (1)

Publication Number Publication Date
ES2571111T3 true ES2571111T3 (es) 2016-05-24

Family

ID=42782289

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11746432T Active ES2571111T3 (es) 2010-04-30 2011-04-29 Método de diagnóstico para predicción de la respuesta de un paciente a la quimioviroterapia o radioviroterapia

Country Status (8)

Country Link
US (1) US9664684B2 (es)
EP (2) EP2383577A1 (es)
JP (1) JP5725463B2 (es)
AU (1) AU2011247360B2 (es)
CA (1) CA2797553C (es)
DK (1) DK2564201T3 (es)
ES (1) ES2571111T3 (es)
WO (1) WO2011134670A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
WO2013112942A1 (en) * 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
CA2863523A1 (en) 2012-02-02 2013-08-08 Board Of Regents, The University Of Texas System Recombinant adenovirus expressing cancer antigens
CN103941009B (zh) * 2014-04-14 2016-06-29 河北工程大学 用于牛羊早期妊娠诊断的isg15胶体金试纸条及其制作方法
WO2018132571A1 (en) 2017-01-13 2018-07-19 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
EP3657172A1 (en) 2018-11-22 2020-05-27 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for predicting the clinical response of oncolytic parvovirus h1 (h-1pv) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient´s sample
CN109694871B (zh) * 2019-01-16 2022-06-10 中国药科大学 抗人isg15蛋白抗体基因及其应用
WO2024058504A1 (ko) * 2022-09-16 2024-03-21 (주)한국원자력 엔지니어링 앱스코팔 효과를 갖는, 암의 예방 또는 치료용 조성물 및 이를 이용한 암의 예방 또는 치료방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239928T3 (es) * 2002-05-09 2009-02-16 Oncolytics Biotech Inc. Metodo para reducir el dolor utilizando virus oncoliticos.
WO2006004907A2 (en) * 2004-06-28 2006-01-12 The Johns Hopkins University Methods of inhibiting viral replication
JP4651495B2 (ja) * 2005-10-14 2011-03-16 日本製粉株式会社 Ｉｓｇ１５タンパク質と特異的に反応するモノクローナル抗体及びそれを産生するハイブリドーマ並びに癌およびウイルス感染の検出方法
US8435731B2 (en) * 2006-01-11 2013-05-07 Colorado State University Research Foundation Markers for viral infections and other inflammatory responses
WO2008115478A2 (en) * 2007-03-19 2008-09-25 University Of Medicine And Dentistry Of New Jersey Method of cancer detection and treatment
ES2402138T3 (es) * 2007-12-28 2013-04-29 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Terapia contra el cáncer con un parvovirus combinado con quimioterapia

Also Published As

Publication number Publication date
EP2564201A2 (en) 2013-03-06
WO2011134670A2 (en) 2011-11-03
CA2797553A1 (en) 2011-11-03
JP5725463B2 (ja) 2015-05-27
EP2564201B1 (en) 2016-03-09
CA2797553C (en) 2017-10-17
US20130101989A1 (en) 2013-04-25
JP2013524823A (ja) 2013-06-20
AU2011247360A1 (en) 2012-11-08
US9664684B2 (en) 2017-05-30
WO2011134670A3 (en) 2012-01-12
DK2564201T3 (en) 2016-05-17
EP2383577A1 (en) 2011-11-02
AU2011247360B2 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
ES2571111T3 (es) Método de diagnóstico para predicción de la respuesta de un paciente a la quimioviroterapia o radioviroterapia
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
BR112014018433A8 (pt) Métodos para determinar o período circadiano em um indivíduo humano e um tau de um paciente, para tratar um paciente humano, para fornecer informação relativa a um ritmo circadiano do paciente, e para converter dados da concentração de melatonina ou substituto de melantonina nos dados do ritmo circadiano, sistema, e, meio de armazenagem legível por computador
BR112014014118A2 (pt) composições branqueadoras de cuidado oral
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
IN2012DN01869A (es)
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
CO6680609A2 (es) Composición acuosa que contiene bromhexina
EP2061907A4 (en) Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
BRPI0821145B8 (pt) uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido
MX380588B (es) Ratones de m-csf humanizada.
MX2013005564A (es) Medicamentos de canabinoides en bajas dosis.
GB2467467B (en) TAZ/WWTR1 for diagnosis and treatment of cancer
AR090354A1 (es) Metodos para determinar la exposicion a la luz ultravioleta
MX2015013784A (es) C. novyi para el tratamiento de tumores solidos en humanos.
SG10201808208PA (en) Agent comprising imidazole dipeptide
BR112012003390A2 (pt) método de radioiodação de uma unidade de marcação biológica, composto, composição radiofarmacêutica, método de preparação do composto, usos de um compsto, e de um aparelho sintetizador automatizado, cassete estéril, de uso único, e, métodos para gerar uma imagem de um corpo de animal ou de humano, e para monitorar o efeiro de tratamento de um corpo de aninmal ou de humano com uma droga.
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
CY1119653T1 (el) Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης
BR112013017445A2 (pt) métodos de determinar a necessidade de um indivíduo para um desfibrilador cardíaco implantado (icd) e para uma terrapia antiarrítmica, de determinar o risco de um indivíduo para uma morte cardiáca súbita, para arritmias e para insuficiência cardíaca, de reduzir risco de morte cardíaca súbita em um indivíduo, kit, sistema, meio de armazenamento legível por computador, e, método implementado por um processador em um computador
RU2013138721A (ru) Способы и наборы для прогнозирования риска дыхательной недостаточности, почечной недостаточности или тромбопении у пациента, страдающего сепсисом, путем измерения уровней эндокана в крови
ECSP14013267A (es) Anestesico para peces y metodo
AR105792A2 (es) Método para el tratamiento de biomasa
DK1889920T3 (da) In vitro fremgangsmåde atil identifikation af forbindelse atil cancerterapi